Dice Therapeutics
Dice Therapeutics, based in South San Francisco, California, focuses on developing oral small molecule therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes treatments targeting IL-17, integrins, and PD-L1.
Services
Dice Therapeutics focuses on developing innovative oral medicines for autoimmune and inflammatory diseases. The company is dedicated to creating therapeutics that target specific protein interactions, offering alternatives to treatments that are currently limited to injectable forms.
Lead Program: IL-17 Cytokine
Dice Therapeutics' lead program targets the IL-17 cytokine, which is significant in the treatment of psoriasis and other IL-17 mediated diseases. This program exemplifies the company's mission to create oral small molecule solutions for conditions traditionally treated with injectable drugs.
Unique DELSCAPE Platform
The DELSCAPE platform is central to Dice Therapeutics' research and development. This platform identifies selective oral small molecules that modulate protein-protein interactions, enabling the creation of therapeutics that are both innovative and effective.
Pipeline and Clinical Trials
Dice Therapeutics' pipeline includes oral small molecule therapeutics targeting IL-17, integrins, and PD-L1 for various diseases. The company is actively conducting a Phase 1 trial for DC-853 and a Phase 2b trial for DC-806, focusing on the treatment of psoriasis.
Location and Headquarters
Dice Therapeutics is located in South San Francisco, California. This strategic location places the company in proximity to a prominent biotech hub, fostering collaboration and innovation in the life sciences sector.